Nazarbayev University Medical Center Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3

Organization Overview

First Clinical Trial
2018
NCT03594877
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Nazarbayev University | Nazarbayev University Medical Center | philip.lafleur@nu.edu.kz

Active Ingredients

Drugs in Phase 3 Trials (1)

ropivacaine (naropin) (1 trial)

Drugs in Phase 2 Trials (6)

arsenic trioxide (trisenox) (1 trial)

d-isoascorbic acid (1 trial)

fluorouracil (efudex) (1 trial)

irinotecan (Camptosar) (1 trial)

leucovorin (1 trial)

oxaliplatin (eloxatin) (1 trial)

Drugs in Phase 1 Trials (1)

nicotine (nicorette) (1 trial)

Drugs in Other Trials (1)

mare milk (2 trials)

Indications

Overview

  • Highest Phase: Phase 3
  • # of Trials: 5
  • # of Trial APIs: 9